Alx Oncology Holdings Inc
ALXO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810182
In the last 90 days, Alx Oncology Holdings Inc insiders filed 0 open-market purchases and 3 sales; 93 institutions reported holding it in 13F filings for Q2 2026, worth $219.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $8.27K in total
- 3
- 13F holdersQ2 2026, +25 vs. previous quarter
- 93
- 13F valueReported value at the end of Q2 2026
- $219.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ALXO, Q2 2026
No superinvestor reported holding ALXO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Alx Oncology Holdings Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)5:51 PM ET | Aug 17 | 1 day | Lettmann JasonCHIEF EXECUTIVE OFFICER | SSale | −2.23K | $1.93 | −$4.30K | −0.8%294.4K after | |
| Aug 18, 2026 (view filing)5:50 PM ET | Aug 17 | 1 day | Pinto ShellySVP, FINANCE AND CAO | SSale | −573 | $1.93 | −$1.11K | −0.6%87.8K after | |
| Jul 6, 2026 (view filing)4:30 PM ET | Jul 1 | 5 days | Pinto ShellySVP, FINANCE AND CAO | SSale | −1.40K | $2.04 | −$2.86K | −1.6%88.4K after | |
| Mar 23, 2026 (view filing) | Mar 19 | 4 days | Lettmann JasonCHIEF EXECUTIVE OFFICER | SSale | −12.3K | $2.17 | −$26.7K | −4.0%293.6K after | |
| Mar 23, 2026 (view filing) | Mar 19 | 4 days | Pinto ShellySVP, FINANCE AND CAO | SSale | −903 | $2.17 | −$1.96K | −1.0%86.8K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Pinto ShellySVP, FINANCE AND CAO | SSale | −565 | $2.27 | −$1.28K | −0.6%87.7K after | |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Goodman Corey SDirector, 10% Owner | PPurchase | +3.18M | $1.57 | +$5.00M | +60.5%8.45M after | |
| Jan 7, 2026 (view filing) | Jan 6 | 1 day | Pinto ShellySVP, FINANCE AND CAO | SSale | −3.92K | $1.11 | −$4.36K | −4.3%88.3K after | |
| Sep 18, 2025 (view filing) | Sep 16-17 | 2 days | Lettmann JasonCHIEF EXECUTIVE OFFICER | PPurchase | +92.2K | $1.08 | +$99.4K | +43.3%305.1K after | 2 lots |
| Aug 20, 2025 (view filing) | Aug 18 | 2 days | Shantharam HarishChief Financial Officer | PPurchase | +75.0K | $0.78 | +$58.5K | New position75.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Alx Oncology Holdings Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13,011,849 | $26.9M | 0.23% | 00.0% | Unchanged |
| venBio Partners LLC | 12,884,638 | $26.7M | 5.14% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,399,530 | $15.3M | 0.00% | +6,951,731+1,552.4% | Added |
| Redmile Group, LLC | 7,392,504 | $15.3M | 1.03% | −571,684−7.2% | Reduced |
| Blackstone Group Inc. | 6,593,543 | $13.6M | 0.04% | +766,999+13.2% | Added |
| Driehaus Capital Management LLC | 6,025,240 | $12.5M | 0.07% | +290,620+5.1% | Added |
| Silverarc Capital Management, LLC | 5,744,757 | $11.9M | 1.32% | +5,744,757 | New |
| TCG Crossover Management, LLC | 5,655,487 | $11.7M | 0.28% | −7,356,362−56.5% | Reduced |
| Vanguard Capital Management LLC | 4,973,436 | $10.3M | 0.00% | +793,700+19.0% | Added |
| Vivo Capital, LLC | 3,184,713 | $6.59M | 0.60% | 00.0% | Unchanged |